Antiretroviral Therapy and Detection of High-grade Cervical Intraepithelial Neoplasia (CIN2+) at Post-CIN Management Follow-up Among Women Living With Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis. by Atemnkeng, Njika et al.
LSHTM Research Online
Atemnkeng, Njika; Aji, Abang Desmond; de Sanjose, Silvia; Mayaud, Philippe; Kelly, Helen; (2020)
Antiretroviral therapy and detection of high-grade cervical intraepithelial neoplasia (CIN2+) at post-
CIN management follow-up among women living with HIV: a systematic review and meta-analysis.




Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
 
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of 
America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of 
America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 
Antiretroviral therapy and detection of high-grade cervical intraepithelial neoplasia 
(CIN2+) at post-CIN management follow-up among women living with HIV: a systematic 
review and meta-analysis 
 
Njika ATEMNKENG1, Abang Desmond AJI2, Silvia de SANJOSE3,4, Philippe MAYAUD1, Helen 
KELLY1,3  
 
1Clinical Research Department, London School of Hygiene and Tropical Medicine, London, 
United Kingdom 
2Faculty of science, University of Buea, Cameroon 
3Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, 
L’Hospitalet de Llobregat, Barcelona, Spain  
4PATH, Seattle, USA  
 
 
Correspondence to:  











/cid/advance-article-abstract/doi/10.1093/cid/ciaa238/5803381 by London School of H
ygiene & Tropical M






We evaluated the association of ART on CIN2+ detection at follow-up among women living 
with HIV and found that ART was associated with a decreased risk of CIN2+ detection at 
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Background: We evaluated the association of antiretroviral therapy (ART), CD4+ count 
and HIV plasma viral load (PVL) on high-grade cervical intraepithelial neoplasia (CIN2+) 
detection at follow-up after CIN management among women living with HIV (WLHIV). 
Methods: Medline, Embase, Global Health and PubMed were searched from January 1, 
1996 to January 15, 2020. Eligible studies investigated the association of ART, CD4+ count 
or HIV PVL on histology-confirmed CIN2+ detection at follow-up. Summary estimates 
were obtained using random-effects meta-analyses; heterogeneity was examined using I2 
statistic. PROSPERO registration:CRD42018115631. 
Results: Eight studies representing 9 populations were identified, including 1,452 WLHIV 
followed between 6 to 33 months post-CIN management. Pooled data from 8 
populations (n=1,408) suggested weak evidence of a decreased risk of CIN2+ detection at 
follow-up among ART users compared to ART-naïve women (crude odds ratio 
[cOR]=0.70, 95% CI: 0.36-1.36; I2=64.5%, p=0.006; adjusted risk ratio [aRR] from 3 
studies=0.66, 95%CI: 0.20-2.24; I2=78.7%, p=0.009). A significant association was observed 
in high-income countries (cOR=0.24, 95%CI: 0.13-0.45; I2=0.0%, p=0.77) but not in low and 
middle-income countries (cOR=1.13, 95%CI: 0.67-1.92; I2=18.8%, p=0.30). 
In three populations, ART users with HIV PVL <50 copies/ml were less likely to have CIN2+ 
detection at follow-up (vs. ≥50 copies/ml: cOR=0.55, 95%CI: 0.32-0.94; I2=0.0%, p=0.23).  
There was weak evidence of decreased CIN2+ detection at follow-up among WLHIV with 
higher contemporary CD4+ cell counts (≥200 cells/µl vs. <200 cells/µl [cOR=0.36, 95%CI: 
0.04-3.13; I2=81.3%, p=0.021]) and significant evidence among women with a higher nadir 
CD4+ count (≥350 cells/µl vs. <200 cells/µl  [adjusted hazard ratio [aHR]=0.35, 95%CI: 0.15-
0.84; I2=0%, p=0.64]).  
Conclusion: ART may reduce the risk of CIN2+ detection at follow-up; this effect is most 
likely enhanced by a combination of adequate HIV control and excisional CIN treatment. 
Our findings support recommendations of early ART and the integration of CIN2+ 
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Invasive cervical cancer (ICC) is the fourth most common cancer and the fourth leading 
cause of cancer death in women [1]. In 2018, there were 311,365 deaths from ICC 
worldwide, with the vast majority occurring in low and middle-income countries 
(LMICs)[1]. 
The predominance of ICC in LMICs is exacerbated by poor coverage of ICC screening[2], a 
low availability of human papillomavirus (HPV) national vaccine programs[3,4] and a 
concurrent high burden of HIV[5]. 
Compared to HIV-negative women, women living with HIV (WLHIV) are more likely to 
acquire HPV and less likely to clear infection[6], and consequently, have a higher incidence 
of high-grade cervical intraepithelial neoplasia (CIN)[7,8] and ICC[9]. Moreover, WLHIV also 
experience poorer CIN management outcomes, being 3 times more likely to be detected 
with CIN at follow-up compared to HIV-negative women[10].  
A previous meta-analysis showed effective antiretroviral therapy (ART) to be associated 
with a decreased risk of high-risk (HR)-HPV prevalence, CIN incidence and progression, 
and ICC incidence[11]. It did not evaluate the association of ART and CIN detection at 
follow-up following CIN management among WLHIV. Given the improved life expectancy 
of WLHIV following the scale-up of ART worldwide, an in-depth understanding of the 
factors driving poor CIN management outcomes among WLHIV is important for optimal 
patient management and follow-up. 
Previous reviews have aimed to identify the histopathological predictors of CIN detection 
at follow-up of CIN management[10,12–14]. However, none have yet evaluated HIV-related 
predictors  among WLHIV. We aimed to systematically review the literature on the 
association of ART, HIV plasma viral load (PVL), CD4+ cell counts and CIN detection at 
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Medline, Embase, Global Health and PubMed electronic databases were searched from 
Jan 1, 1996 (when highly active ART [HAART] became utilised) to January 15, 2020 
(Appendix A).  authors (N.A. and H.K.) independently assessed the eligibility of each 
paper. Disagreements were resolved by consensus. 
Eligible studies included WLHIV who were managed for CIN, had at least one follow-up 
visit to estimate risk of histology-confirmed high grade CIN (CIN2+) at follow-up and 
evaluated the association of CIN2+ detection at follow-up with at least one of the 
following: ART (at the time of CIN management), HIV PVL (measured at or within 12 
months of CIN management), CD4+ cell count at time of CIN management (baseline), at 
time of follow-up (contemporary) or nadir CD4+ (lowest CD4+ cell count ever recorded). 
Studies which had CIN1 as outcome and/or used only cytology at follow-up of CIN 
management were excluded. 
In this review, we use the term ‘detection at follow-up’ to incorporate the different 
outcomes reported by the authors (Table 1), as it is difficult to distinguish between 
recurrent lesions, new lesions and persistent lesions (treatment failure) at follow-up of 
CIN management.  
Quality assessment 
The Critical Appraisal Skills Program (CASP) tool for cohorts[15] was used to assess 
methodological quality (Appendix B). Studies that enrolled women prior to treatment 
without histological confirmation were considered at risk of misclassification bias, due to 
the low specificity of non-histological diagnostic methods[16]. Studies which included 
participants with a history of failed CIN treatment prior to enrolment were considered at 
risk of bias because these participants may have been at increased risk of poor 
management outcomes.  
We considered both HIV-related confounders (ART use, ART duration, CD4+ cell counts 
(baseline, contemporary and nadir), HIV plasma viral load) and non-HIV related 
confounders. Low-risk studies adjusted for any HIV-related confounders; medium-risk did 
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The form for data extraction was adapted from published guidelines[17] and included 
effect estimates (odds ratios [OR], risk ratios [RR] and hazard ratios [HR]), raw data to 
calculate odds ratios and information to allow for description of study characteristics.  
Adjusted effect estimates were reported where available. For studies in which adjusted 
estimates were not reported but raw data were provided, crude OR were calculated.  
CIN2+ detection at follow-up was compared between WLHIV on ART and ART-naïve 
WLHIV (Analysis 1); between WLHIV with undetectable HIV PVL (<50 copies/ml) and 
WLHIV with detectable HIV PVL (≥50 copies/ml) (Analysis 2). Further analyses compared 
CIN2+ detection at follow-up among WLHIV according to: baseline CD4+ count (≥500 
cells/µl vs. <500 cells/µl), contemporary CD4+ count (≥200 cells/µl vs. <200 cells/µl and 
≥500 cells/µl vs. <500 cells/µl) and nadir CD4+ counts (≥350 cells/µl vs. <200 cells/µl) 
(Analysis 3). The cut-off values for CD4+ counts were chosen to reflect those reported in 
the included studies.  
Data were pooled using a random-effect meta-analysis that accounts for between-study 
heterogeneity[18]. Several subgroup analyses were carried out according to: country 
income level (high/upper-middle income [HMIC] and low/lower middle-income [LMIC], 
using World Bank classification[19]); type of CIN management (excision [loop electrical 
excision therapy and conization] and ablation [cryotherapy, thermo-coagulation and 
laser ablation]) and interval between CIN management and  CIN2+  detection at follow-
up (≤12 months and >12 months). Data were analysed using Stata version 14. 
This systematic review is reported according to the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA)[20] and is registered on the PROSPERO 
database at the Centre of Reviews and Dissemination, University of York; registration 
number CRD42018115631. The review dataset is available on the Mendeley online 
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Four hundred and four records were identified, of which 128 duplicates were removed, 
and 230 records were excluded after title/abstract review, leaving 43 articles for full-text 
review (Figure 1). Of these, 8 articles[21–28], representing 9 discrete populations and 1,452 
women, met the inclusion criteria. One study[24]  provided separate effect estimates for 
two populations: WLHIV who received cryotherapy and WLHIV who received excisional 
therapy.  
The characteristics of the included studies are summarised in Table 1. The WLHIV had a 
median follow-up duration ranging between 6 and 33 months. The proportion of ART 
users ranged between 65% and 92%; between 53% and 65% of WLHIV had HIV PVL <50 
copies/ml and median CD4+ cell counts ranged from 322 cells/µl to 557 cells/µl.  Of the 
three populations that studied the association of ART and CIN2+ detection at follow-up in 
HMICs[22,25,28], excisional management methods were used in one[28] and a combination 
of excision and ablative methods were used in two, although most women were treated 
using excisional methods (77% and 85%)[22,25]. Of the five populations evaluated in LMICs, 
excision and ablative methods were used in two[24,26] and three[23,24,27] populations 
respectively (Table 1). 
For most studies, the main limitations in study quality were due to insufficient 
adjustment of HIV-related confounders and risk of attrition bias (Appendix B). Also, 
although we excluded studies without histopathological confirmation of CIN2+ at follow-
up, there was still risk of misclassification as some included studies had a biopsy 
indication following cytology. There could have been an underestimation of true 
detection at follow-up if some women were excluded from biopsy on the basis of follow-
up cytology results. 
Association of ART and CIN2+ detection at follow-up (Analysis 1) 
Seven studies, representing 8 populations and 1, 408 women assessed the association of 
ART use and CIN2+ detection at follow-up[22–28] There was weak evidence of a decrease in 
CIN2+ detection at follow-up among ART users compared to ART-naïve women (crude 
OR [cOR]=0.70, 95% confidence interval [CI]: 0.36-1.36; I2=64.5%, p=0.006; Figure 2). Three 
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modify the estimate (cRR=0.66, 95%CI: 0.20-2.24; I2=78.7%, p=0.009; adjusted for age, 
CD4+ cell count and WHO clinical stage; data not shown). Excluding two populations[23,26] 
in which 10.6% and 9% of ART users initiated ART after CIN treatment provided statistically 
significant evidence (cOR=0.50, 95% CI: 0.27-0.94; I2=55.8%, p=0.045; data not shown).  
There was a significantly decreased risk in CIN2+ detection at follow-up among ART users 
in studies conducted in high and upper middle-income countries (HMICs)[22,25,28] 
(cOR=0.24, 95%CI: 0.13-0.45; I2=0.0%, p=0.77; Table 2, Appendix C) but not in low and 
lower middle-income countries (LMICs)[23,24,26,27] (cOR=1.13, 95%CI: 0.67-1.92; I2=18.8%, 
p=0.30; Table 2, Appendix C ).  
In 5 populations[22,24–26,28] that used excisional methods for CIN  management, there was 
some evidence of a decreased risk of CIN2+ detection at follow-up among ART users 
compared to ART-naïve WLHIV (cOR=0.53, 95%CI: 0.19-1.52; I2=70.4%, p=0.009) but not in 3 
populations[23,24,27] using ablative methods (cOR=0.92, 95%CI: 0.52-1.65; I2=19.1%, p=0.29; 
Table 2, Appendix D).  
Restricting the meta-analysis to 4 populations[24,25,28] with >12 months interval between 
CIN  management and follow-up, there was weak evidence of a decreased risk in CIN2+ 
detection at follow-up among ART users compared to ART-naïve women (cOR=0.51, 
95%CI: 0.17-1.52; I2=65.7%, p=0.033; Table 2) but not among studies with a ≤12 months 
interval[22,23,26,27], (cOR=0.94, 95%CI: 0.36-2.45; I2=71%, p=0.02; Table 2, Appendix E). 
There was no evidence to suggest publication bias for the association of ART and CIN2+ 
detection at follow-up (p=0.266 and p=0.179 for Begg’s rank correlation test and Egger’s 
weighted regression, respectively; Appendix F). 
Association of HIV plasma viral load and CIN2+ detection at follow-up (Analysis 2) 
In two studies[22,24] representing three populations and 540 WLHIV,  there was significant 
evidence that ART users with undetectable HIV PVL (<50 copies/ml) had a decreased risk 
of CIN2+ detection at follow-up compared to WLHIV on ART with detectable (≥50 
copies/ml) HIV PVL (cOR=0.55, 95%CI: 0.32-0.94; I2=32.4%; p=0.23; Figure 2) 
In another study[21] (n=44), not included in the meta-analysis due to different cut-offs, 
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with HIV PVL >10,000copies/ml compared to WLHIV with HIV PVL<1,000 copies/ml 
(cOR=1.5, 95%CI: 0.33-6.80; data not shown).  
 
Association of baseline, contemporary and nadir CD4+ cell counts and CIN2+ 
detection at follow-up (Analysis 3) 
Seven studies[21–24,26–28], representing 8 study populations and 1,331 WLHIV, assessed 
CD4+ cell count as a possible predictor of CIN2+ detection at follow-up and were included 
in the various sub-analyses (Figure 3; Table 2). 
In 2 studies representing 3 populations[23,24], women with high CD4+ count at the time of 
CIN  management (baseline CD4+) had a non-significant increased risk of CIN2+ detection 
at follow-up (≥500 vs. <500 cells/µl: cOR=1.48, 95%CI: 0.93-2.34; I2=0%, p=0.51; Figure 3, 
Table 2).   
When considering CD4+ count at time of follow-up (contemporary CD4+), women with 
higher contemporary CD4+ cell count had a non-significant decreased risk of CIN2+ 
detection at follow-up compared to women with lower CD4+ cell count (≥200 vs. <200 
cells/µl: cOR=0.36, 95%CI: 0.04-3.13; I2=81.3%, p=0.02; ≥500 vs. <500 cells/µl: cOR=0.71, 
95%CI: 0.29-1.74; I2=22.1%, p=0.28; Figure 3, Table 2).  
In two studies[22,26], nadir CD4+ count ≥350 cells/µl [22,26] was associated with a 65% 
decreased risk of CIN2+ detection at follow-up compared to nadir CD4+ <200 cells/µl  
(aHR=0.35, 95%CI: 0.15-0.84; I2=0%, p=0.64; adjusted for age and region; Figure 3 and 
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In this meta-analysis, ART was associated with a reduced risk of CIN2+ detection at 
follow-up, particularly among ART users in HMICs. Also, a significantly lower risk of CIN2+ 
detection at follow-up was found among WLHIV with undetectable HIV PVL and WLHIV 
with high nadir CD4+ cell counts. 
The difference in the effect of ART according to country income category may be 
attributable to different factors. First, compared to WLHIV in LMICs, WLHIV in HMICs are 
more likely to be on effective ART (i.e. have undetectable HIV PVL) possibly due to better 
access and adherence to ART, a higher likelihood of initiating ART earlier at higher CD4+ 
cell counts and a greater probability of retention in care[29]. Second, women in HMICs are 
more likely to undergo excisional management which has been shown to be more 
effective than ablative CIN management among WLHIV[24,30] and, as shown in our results, 
ART is perhaps more likely to be beneficial following excisional management. The link 
between adequate HIV control and improved CIN management outcomes was supported 
by the lower risk of CIN2+ detection at follow-up among WLHIV with undetectable HIV 
PVL and among WLHIV with higher CD4+ cell counts. Furthermore, the significant benefit 
of ART which was observed after exclusion of studies where about 10% of ART users 
initiated ART after CIN management, though possibly due to chance, could also point to 
the significance of the timing of ART use in improving CIN management outcomes. A 
large cohort of South African women (n=778), found a 30% decreased risk of CIN1+ 
detection at follow-up among WLHIV who initiated ART prior to CIN management 
compared to WLHIV who initiated ART after CIN management[31]. 
The finding that ART reduced the risk of CIN2+ detection at follow-up after excisional but 
not after ablative CIN management contrasts the findings of a recent meta-analysis 
indicating no difference in the prevalence of high-grade lesions at follow-up among 
WLHIV that underwent excisional versus ablative methods. However, there was no direct 
comparison between both treatment methods and the inclusion of cytology at follow-up 
could have introduced bias[32]. In support of a superior effect of excisional therapy, it may 
be postulated that, given the multiple immune evasion mechanisms employed by HR-
HPV[33,34] it is harder for immunosuppressed WLHIV to mount an effective HPV-specific 
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(such as excision which cuts 15mm deep whilst ablation cuts 7-8mm deep[35]) stand a 
better chance of eradicating the HPV virus. This is supported by a recent meta-analysis 
where WLHIV with positive margins had 3 times the odds of failing treatment compared 
to WLHIV with negative margins[32].  
ART was associated with some improvement in outcome among studies which followed 
women over 12 months but not among studies with a shorter follow-up duration (≤12 
months). In the studies included in this review, lesions may have continued to occur even 
after the end of the studies, particularly in studies with a shorter duration of follow-up. In 
fact, findings from a 15-year long cohort study among 37,142 women in Canada suggested 
a cut-off of 6 years follow-up to detect the largest number of post-management CIN 
lesions[36]. 
WLHIV on ART with undetectable HIV PVL had a significantly lower risk of CIN2+ 
detection at follow-up compared to WLHIV on ART with detectable HIV PVL. However, 
based on data from the included studies, it is not clear whether WLHIV with viral 
suppression (at WHO recommended cut-off of 1000 copies/ml, which is widely used for 
clinical management of HIV disease and a routinely monitored indicator) fare better than 
women with no suppression (ineffective ART). One study found no difference in the risk 
of CIN1+ detection at follow-up between WLHIV with ‘virological failure and WLHIV with 
‘no virological failure’, although the definition of ‘virological failure’ was unclear and, 
given the time-dependent nature of HIV PVL, there was potential misclassification, as the 
time relationship between the measurement of HIV PVL and CIN management or follow-
up was not considered[31]. Furthermore, CIN1 is not an adequate endpoint to measure risk 
of cervical cancer. 
The association between lower CD4+ cell counts and an increased risk of CIN detection at 
follow-up, though non-significant, was consistent across most CD4+ cell count cut-offs 
considered. This is biologically plausible because CD4+ cells are essential for the immune 
control of HR-HPV infection[33]. Strangely, there was some evidence suggesting a higher 
risk of CIN2+ detection at follow-up with baseline CD4+ ≥500 cells/µl. We think this was 
possibly confounded as they were all crude estimates and the finding diverged from 
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count >350 cells/µl was associated with a decreased risk of CIN2+ detection at follow-up. 
This could reflect baseline CD4+ cell count which was not accounted for and, one study 
found no effect of nadir CD4+ cell count on CIN2+ detection at follow-up after adjusting 
for baseline CD4+ cell count[22]. However, it also supports the suggestion of a CD4+ nadir 
threshold below which subsequent ART-induced immune reconstitution does not 
optimally protect against serious non-AIDS events such as CIN[37]. Therefore, although 
nadir CD4+ cell count is a known strong predictor of  CIN2+ incidence and progression[38], 
it could also be an important risk factor for poor CIN management outcomes.  
Taken all together, it is reasonable to say that ART may reduce the risk of CIN2+ 
detection at follow-up but this association is likely influenced by a combination of 
adequate HIV control (recovery of cellular immunity and suppression of HIV PVL) and 
excisional CIN treatment, factors which are less likely in LMICs where the burden of HIV 
and invasive cervical cancer is highest. 
There are some limitations to this study.  
Although studies reporting on CIN1 at follow-up were excluded (as CIN1 is has recently 
been considered a manifestation of acute HPV infection and not a true precursor lesion 
of cervical cancer[39]), CIN2 is still subject to misclassification as its diagnosis has poor 
replicability and a high proportion regress spontaneously[40]. Therefore, as no studies 
reported solely on CIN3, the real precursor lesion of cervical cancer[41], residual 
misclassification of precancerous lesions cannot be ruled out. 
The few number of studies that met our inclusion criteria underscores the important 
variability across studies of CIN and HIV, including: different criteria for treating CIN 
lesions, different management techniques, different cut-offs for defining lesion detection 
at follow-up (low- or high-grade) and follow-up duration, differing biopsy indications and 
differences in the prevalence and adjustment of potential confounders. These perhaps 
contributed to the significant heterogeneity observed in some analyses. Also, most of 
the included studies were at medium-to-high risk of bias/confounding due to lack of 
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Also, confounding by treatment indication[42] is inherent to ART studies conducted prior 
to the era of universal ART; this is because in these studies, women on ART were more 
likely to be of an advanced HIV clinical or immunological stage and perhaps more likely to 
have poorer CIN management outcomes as a consequence. This may have diluted the 
beneficial effect of ART or immune reconstitution in reducing the risk of CIN2+ detection 
at follow-up.  
Another limitation was our inability to further explore the impact of the duration of ART 
use on the risk of CIN2+ detection at follow-up, as only one study investigated this[23]. 
This study found a non-significant paradoxical increase in the risk of  CIN2+ detection at 
follow-up with increasing duration on ART (>2 years versus <2 years). These were 
however unadjusted estimates with a short follow-up duration (6 months) and there may 
also have been an influence of confounding by indication, as ART started at CD4+ counts 
<250 cells/µl. In a previous meta-analysis, long-term ART users (≥2 years) had a lower 
prevalence of CIN2+ compared with <2 years and ART-naïve combined[11]. It would have 
been interesting to see if this translates into a decreased risk of CIN2+ detection at 
follow-up following management and further help prioritize WLHIV who should be 
monitored more closely for detection at follow-up. 
Despite the limitations, this is the first systematic review and meta-analysis to evaluate 
the association of ART and other HIV-related factors with CIN2+ detection at follow-up 
after CIN management among WLHIV. It included information from among nearly 1,500 
WLHIV and several sub-analyses were done to investigate bias and heterogeneity.  
Although most of the included studies were carried out when ART was initiated at low 
CD4+ cell counts, these findings are still very useful especially for LMICs which have the 
highest burden of cervical cancer and where, despite the current push for universal ART, 
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Our findings support early ART i.e. starting ART for all WLHIV irrespective of CD4+ cell 
counts, as they will likely have better CIN management outcomes. The integration of 
cervical cancer screening and management into HIV care could be beneficial, such that 
WLHIV with CIN who are not adequately controlled with ART should be monitored at 
closer intervals for CIN2+ detection at follow-up of CIN management.  
Going forward, there is a need for more consensus in treatment indications, definitions 
of lesion at follow-up (‘treatment failure’, ‘recurrence’, ‘persistence’), minimum 
acceptable follow-up duration and CIN diagnostic methods. There is also need for longer 
term follow-up studies especially as women are being treated at increasingly higher CD4+ 
cell counts. These are important for future study designs and for a better understanding 
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Baseline CD4= CD4 at the time of CIN treatment. Contemporary CD4= CD4 at the time of CIN detection at follow-up. Nadir CD4= lowest CD4+ 
cell count ever recorded. n=sample size. cOR=crude odds ratio. aRR=adjusted risk ratio. aHR=adjusted hazards ratio. CIN2+=Cervical 
Intraepithelial Neoplasia, grade 2 or higher. In one study (Carlander, 2018), 77% of women had were managed using excisional methods.  
 
ART= antiretroviral therapy. PVL=HIV plasma viral load. n=sample size. cOR=crude odds ratio. aRR=adjusted risk ratio. aHR=adjusted hazards 
ratio.  CIN2+=Cervical Intraepithelial Neoplasia, grade 2 or higher. Exposed= ‘ART’ or ‘Undetectable PVL’. Unexposed= ‘ART-naïve’ or 
‘detectable PVL’. In one study (Carlander, 2018), 77% of women had were managed using excisional methods and, in another study, (Heard, 
2005), 85% of women had were managed using excisional methods. 
 
 






Figure 2: Meta-analysis of the association of ART on CIN2+  detection at follow-up (Analysis 1) and HIV 







Figure 3: Meta-analysis of the association of CD4+ cell count on CIN2+ detection at follow-up          
(Analysis 3)  
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Outcome definition   
Babkina, 
2015[21] 
Cohort USA (New 
Jersey) 
CIN2+ 44 Ageα=44y Conisation  24 ‘Persistent or residual 
disease’ defined as CIN2/3 
on repeat excision 





CIN2+ 140 Ageα=34y; 65% on HAART; 53% with 





7 ‘Treatment failure’ defined 
as the presence of CIN2+ 
on cervical cytology/ 
histology at initial follow-






CIN2+ 79 Ageα=41 years; 77% on HAART; 
Median CD4+ =322/µl 
Cryotherapy 6 ‘Residual disease’ defined 
as histologically confirmed 





CIN2+ 200 Ageα=38 years; Median CD4+=371/µl; 
86% on HAART; 63% with 
undetectable HIV PVL 
Cryotherapy 24 ‘Recurrence’ defined as 
cumulative post-
management CIN2+ over a 






CIN2+ 200 Ageα=37 years; Median CD4+=385/µl; 
92% on HAART; 65% with 
undetectable HIV PVL 
LEEP 24 ‘Recurrence’ defined as 
cumulative post-
management CIN2+ over a 
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CIN 2+ 121 Ageα=33 years; Median CD4+=327/µl; 
Median HIV-PVL = 499/ml  
Laser vaporisation, 
LEEP 
20  ‘Recurrence’ defined as 
high-grade CIN post-
treatment diagnosed 
within 3 months after 
surgery or, in the 
absence of biopsy, by at 
least 2 consecutive 
abnormal Papanicolaou 







CIN2+ 283 Ageα =33 years; 65% on HAART; 
Median CD4+α =418/µl 
LEEP 6 ‘Recurrence’ defined as 






VIA+ 330 Ageα=35 years; 87% on HAART; 
Median CD4+α = 410/µl 
Cryotherapy 11 ‘Post-treatment detection 
at follow-up’ defined as 
biopsy- confirmed CIN2+ at 
follow-up ; women with 
negative VIA, Pap smear, 
and HR-HPV testing were 




Cohort Brazil (Rio 
de Janeiro) 
CIN2+ 29 Ageα=32 years; 85% on HAART; 
Median CD4+α =557/µl 
LEEP 33 ‘Recurrence’ defined as 





A=Arranged alphabetically. n=sample size. FU=follow-up. α=mean or median value. CIN2+=Cervical Intraepithelial Neoplasia, grade 2 or higher. VIA+=positive lesions on visual inspection with acetic acid. 
LEEP=Loop electrosurgical excision procedure. LLETZ=Large loop excision of the transformation zone. CKC=Cold knife conisation. HAART=Highly-active antiretroviral therapy (≥3 drugs belonging to at 
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Criteria  Stratification n 
populations 
Estimate 
 (95% CI) 
I2 P for 
heterogeneity 
ART vs. ART naïve  8 0.70 (0.36-1.36) 64.5% 0.006 
Country income HMIC[22,25,28] 3 0.24 (0.13-0.45)  0.0%,  0.77 
LMIC[23,24,26,27] 5 1.13 (0.67-1.92)  18.8% 0.30 
Follow-up duration >12 months[24,25,28] 4 0.51 (0.17-1.52) 65.7%,  0.03 
≤12 months[22,23,26,27] 4 0.94 (0.36-2.45) 71.0% 0.02 
Intervention Ablative[23,24,27] 3 0.92 (0.52-1.65) 19.1% 0.29 
Excision[22,24–26,28] 5 0.53 (0.19-1.52) 70.4% 0.009 
  
Undetectable vs. detectable HIV PVL  (<50 
vs ≥50 copies/ml)[22,24] 
 
3 0.55 (0.32-0.94) 32.4% 0.23 
CD4+ count, (cells/µl)  
Baseline CD4+ ≥500 vs. <500[23,24]  3 1.48 (0.93-2.34) 0.0% 0.51 
Contemporary CD4+ ≥200 vs. <200[22,23] 2 0.36 (0.04-3.13) 81.3% 0.02 
≥500 vs. 
<500[22,23,28] 
3 0.71 (0.29-1.74) 22.1% 0.28 
≥500 vs. 
<200[21,22,27] 
3 0.68 (0.33-1.41) 10.4% 0.33 
Nadir CD4+ ≥350 vs. <200[22,26] 2 0.35 (0.15-0.84)  0.0% 0.64 
ART=antiretroviral therapy. HIV PVL= HIV plasma viral load. CIN=cervical intraepithelial neoplasia. CI=confidence interval. n=number of 
studies. HMIC=High and upper-middle income countries. LMIC=Low and lower-middle income countries.  CIN2+=Cervical Intraepithelial 
Neoplasia, grade 2 or higher. Baseline CD4+=CD4+ at the time of CIN treatment. Contemporary CD4+= CD4+ at the time of CIN 
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Subgroup (I−squared = 0.0%, p = 0.639)
Huchko, 2014
Carlander, 2018
Nadir CD4+ ≥350 vs. <200 cells/µl




Contemporary CD4 ≥500 vs. <500 cells/µl
Subgroup (I−squared = 81.3%, p = 0.021)
DeVuyst, 2014
Carlander, 2018
Contemporary CD4 ≥200 vs. <200 cells/µl
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